Long Ridge
Purchase-Price Allocation
Goodwill
$90.3M
Assets Acquired
$1.78B
Liabilities Assumed
$1.38B
Deferred Tax Liability
$197.8M
2 years of history · ending 2025-12-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | -0.45% | -0.06% | 1.77% | 1.79% | -1.11% | -0.41% |
| Foreign Rate Differential | 0.06% | 0.00% | 0.00% | — | — | — |
| Other Adjustments | 0.06% | -4.43% | 0.46% | -0.61% | 0.33% | -0.35% |
| SBC (Nondeductible) | — | — | — | — | — | 1.26% |
| Nondeductible Expenses | — | — | — | — | — | -1.42% |
| Valuation Allowance Change | -22.13% | -23.05% | -23.09% | -17.88% | -14.65% | -35.83% |
| Effective Tax Rate | 2.69% | 3.37% | -2.44% | -1.58% | -1.26% | 2.16% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$2.0M | −$3.6M | $4.5M | $2.5M | $3.3M | −$3.3M |
| Income Taxes Paid (Cash) | $329.0K | $334.0K | $379.0K | $459.0K | $457.0K | — |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Purchase-Price Allocation
Goodwill
$90.3M
Assets Acquired
$1.78B
Liabilities Assumed
$1.38B
Deferred Tax Liability
$197.8M
Purchase-Price Allocation
Assets Acquired
$1.43B
Liabilities Assumed
$309.6M
Deferred Tax Liability
$273.4M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).